Get the Stockscreener App
2.20
1.35%
-0.03
Sab Biotherapeutics Inc stock is traded at $2.20, with a volume of 117.27K.
It is down -1.35% in the last 24 hours and down -14.73% over the past month.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
See More
Previous Close:
$2.23
Open:
$2.19
24h Volume:
117.27K
Relative Volume:
0.09
Market Cap:
$20.44M
Revenue:
-
Net Income/Loss:
$-45.57M
P/E Ratio:
-0.3492
EPS:
-6.3
Net Cash Flow:
$-38.56M
1W Performance:
-1.35%
1M Performance:
-14.73%
6M Performance:
+6.80%
1Y Performance:
-18.82%
1-Day Range:
$2.13
$2.2575
1-Week Range:
$2.1201
$2.3929
52-Week Range:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Compare SABS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.20 | 20.34M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Oct-09-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Stock (SABS) Latest News
Risk adjusted return profile for SAB Biotherapeutics Inc. Equity Warrant analyzedFree Trade Timing Strategy With Technical Data - Newser
Can swing trading help recover from SAB Biotherapeutics Inc. Equity Warrant lossesCapital Growth Plan for New Investors - Newser
Analyzing SAB Biotherapeutics Inc. with multi timeframe chartsCapital Growth Plan for New Investors - Newser
SAB Biotherapeutics Inc. Equity Warrant stock retracement – recovery analysisShort Term Momentum Based Trading Strategy - Newser
Price momentum metrics for SAB Biotherapeutics Inc. explainedPredictable Return Strategy with AI Support - Newser
Applying Elliott Wave Theory to SAB Biotherapeutics Inc. Equity WarrantLong-Term Signal Tracking and Profit Summary - Newser
What makes SAB Biotherapeutics Inc. Equity Warrant stock price move sharplyFree Triple Digit Return Stock Predictions - Newser
SAB Biotherapeutics Inc. stock volume spike explainedMinimal Risk Growth Investment Opportunity Analysis - Newser
Chardan Capital Issues Pessimistic Forecast for SAB Biotherapeutics (NASDAQ:SABS) Stock Price - Defense World
Will SAB Biotherapeutics Inc. stock benefit from interest rate changesFree Trade Timing Strategy With Technical Data - Newser
Measuring SAB Biotherapeutics Inc.’s beta against major indicesFree Short Term Trading Opportunity Watch - Newser
SAB Biotherapeutics Inc. stock chart pattern explainedAI Trend Detection for Entry Timing - Newser
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - MSN
Technical analysis overview for SAB Biotherapeutics Inc. stockDaily Pick Forecast with Entry Zones - Newser
Should you hold or exit SAB Biotherapeutics Inc. Equity Warrant nowLong-Term Investment Strategy Summary Guide - Newser
What the charts say about SAB Biotherapeutics Inc. todayValue Holding Return Summary With Outlook - Newser
How hedge fund analytics apply to SAB Biotherapeutics Inc. Equity Warrant stockPredictable Income Summary for Long-Term Trades - Newser
Is SAB Biotherapeutics Inc. Equity Warrant Stock a Smart Buy in 2025 Investment Analysis InsideMulti-Bagger Detection with Trend Tools - Newser
Top chart patterns to watch in SAB Biotherapeutics Inc.Daily Market Momentum Summary and Strategy - Newser
Why SAB Biotherapeutics Inc. Equity Warrant stock attracts strong analyst attentionLow Risk Strategy with Smart Entry Zones - Newser
Chardan Capital lowers SAB Biotherapeutics stock price target to $12 from $20 - Investing.com Canada
SAB Biotherapeutics 2024 Q4 Earnings Significant Loss Widening Despite Revenue Decline - AInvest
What high frequency data says about SAB Biotherapeutics Inc. Equity WarrantDownside Risk Evaluation and Stock Analysis - Newser
SAB Biotherapeutics Reports Increased Losses Amid Funding Boost - TipRanks
SAB Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SAB Biotherapeutics Secures $175M Funding, Paving Way for Phase 2b Diabetes Trial and Justifying Buy Rating - TipRanks
SAB Biotherapeutics Expected to Beat Earnings Estimates Ahead of Q2 Release. - AInvest
SAB Biotherapeutics reports Q2 EPS ($1.09) vs. (79c) last year - TipRanks
SAB Bio reports strong cash position with completed financing extending operational runway - MarketScreener
SAB BIO raises $175 mln, extends runway to mid-2028, initiates Phase 2b study in Q3 2025 - AInvest
SAB Biotherapeutics, Inc. SEC 10-Q Report - TradingView
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates - GlobeNewswire
SAB Bio Lands Massive $175M Investment from Sanofi for Revolutionary Type 1 Diabetes Treatment - Stock Titan
SAB Biotherapeutics (SABS) to Release Earnings on Thursday - Defense World
SAB Biotherapeutics Inc. Earnings Report Breakdown: What Investors Should KnowWeekly Gain Forecast with Momentum Indicators - Newser
SAB BIO Raises $175 Million in Oversubscribed Private Placement - Global Legal Chronicle
SAB Biotherapeutics Inc expected to post a loss of 80 cents a shareEarnings Preview - TradingView
SAB Biotherapeutics Inc. Could See a Relief Rally From SupportRisk Controlled Short Term Trade Plans Published - beatles.ru
What is the risk reward ratio of investing in SAB Biotherapeutics Inc. stockAchieve rapid financial growth with smart picks - Jammu Links News
What are the technical indicators suggesting about SAB Biotherapeutics Inc.Unmatched profit growth - Jammu Links News
Live Scanner Shows Breakout on SAB Biotherapeutics Inc. Equity WarrantWatchlist for Low Risk High Return Stocks Updated - metal.it
What institutional investors are buying SAB Biotherapeutics Inc. Equity Warrant stockUnlock powerful trading strategies for gains - Jammu Links News
Is SAB Biotherapeutics Inc. stock overvalued or undervaluedSkyrocketing returns - Jammu Links News
SAB Biotherapeutics Inc. Stock Analysis and ForecastFree Expert Stock Watchlist - Jammu Links News
What institutional investors are buying SAB Biotherapeutics Inc. stockCapitalize on fast-moving trading opportunities - Jammu Links News
Is SAB Biotherapeutics Inc. a growth stock or a value stockBuild a diversified portfolio for steady growth - Jammu Links News
When is SAB Biotherapeutics Inc. stock expected to show significant growthBoost your returns with professional guidance - Jammu Links News
What are analysts’ price targets for SAB Biotherapeutics Inc. in the next 12 monthsBuild a portfolio with strong long-term growth - Jammu Links News
Published on: 2025-08-03 17:18:17 - Jammu Links News
What is the risk reward ratio of investing in SAB Biotherapeutics Inc. Equity Warrant stockInvest smarter with advanced market data - Jammu Links News
What high frequency data says about SAB Biotherapeutics Inc.Momentum-Based Prediction for Quick Returns - Newser
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):